eMed vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 54)
eMed logo

eMed

ChallengerDigital Health

Metabolic Health

Raised $200M Series A (Mar 2026) at $2B+ valuation led by AON Consulting. 91%+ medication adherence. GLP-1 benefits platform for employers. Linda Yaccarino CEO.

AI VisibilityBeta
Overall Score
C54
Category Rank
#208 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
60
Perplexity
55
Gemini
52

About

eMed is a GLP-1 and metabolic health benefits platform built specifically for employer-sponsored health plans, the fastest-growing category in US workplace benefits. The company raised $200 million in Series A financing in March 2026 at a $2 billion+ valuation led by AON Consulting, with backing from Linda Yaccarino (former Twitter/X CEO, now eMed CEO) and Tom Brady. Claiming 91%+ medication adherence rates, eMed positions itself as the most effective GLP-1 benefits program available to employers.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

54
Overall Score
90
#208
Category Rank
#2
77
AI Consensus
83
stable
Trend
stable
60
ChatGPT
92
55
Perplexity
93
52
Gemini
89
50
Claude
96
55
Grok
95

Key Details

Category
Metabolic Health
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only eMed
Metabolic Health

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.